| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q01DX005 (ip) | optimum tumor weight change | saline | 26.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 00/08 animals surviving on day 31 |
| Q01DX005 (ip) | optimum tumor weight change | saline | 32.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 00/08 animals surviving on day 31 |
| Q01DX005 (ip) | optimum tumor weight change | saline | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 00/08 animals surviving on day 31 |
| Q01DX005 (ip) | optimum tumor weight change | saline | 50.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 01/08 animals surviving on day 31 |
| Q07DX002 (ip) | median tumor weight (est.) | saline | 8.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 14; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | saline | 16.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 14; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | saline | 32.0 mg/kg/injection | 13.0 | Antitumor endpoint evaluated on day 14; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | saline | 64.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 14; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | saline | 128.0 mg/kg/injection | 1.0 | Antitumor endpoint evaluated on day 14; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | saline | 256.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 14; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | suspension in saline | 8.0 mg/kg/injection | 85.0 | Antitumor endpoint evaluated on day 14; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | suspension in saline | 16.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 14; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | suspension in saline | 32.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 14; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | suspension in saline | 64.0 mg/kg/injection | 61.0 | Antitumor endpoint evaluated on day 14; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | suspension in saline | 128.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 14; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q07DX002 (ip) | median tumor weight (est.) | suspension in saline | 256.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 14; 07/10 animals surviving on tox evaluation day (usually day 5) |